2024-519639-40-00RecruitingPhase 1
A First-in-human Study to Evaluate the Safety and Anticancer Effect of Several Doses of TH9619 in Patients with Advanced Cancer (ODIN).
One-carbon Therapeutics AB3 sites in 2 countries33 target enrollmentStarted: April 11, 2025Last updated:
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- Enrollment
- 33
- Locations
- 3
Study Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 65+ years (18-64 Years, 65+ Years)
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Ana Slipicevic
Scientific
One-carbon Therapeutics AB
Study Sites (3)
Loading locations...
Similar Trials
Recruiting
Phase 1
Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors2022-502867-39-00Amgen Inc.58
Recruiting
Phase 1
A first study in humans testing the safety and effects of KUP-101A in patients with certain advanced solid cancers2025-522402-21-00Kupando GmbH21
Recruiting
Phase 1
First in human clinical trial to evaluate the safety, tolerability and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer2022-503084-15-00Deutsches Krebsforschungszentrum (DKFZ)77
Recruiting
Phase 1
A first-in-human trial to evaluate safety, tolerability, and pharmacokinetics of single and multiple oral doses of Debio 1453P in healthy adults2024-519328-26-01Debiopharm International S.A.88
Active, not recruiting
Phase 1
Study to evaluate QR-421a in subjects with retinitis pigmentosa (RP) due to mutations in exon 13 of the USH2A GeneEUCTR2018-002433-38-FRProQR Therapeutics18